Kalvista Pharm Stock Price, News & Analysis

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company, will present at the 13th Annual Jefferies Global Healthcare Conference on June 8, 2022, at 11:30 a.m. ET. The presentation will focus on its pipeline of small molecule protease inhibitors, including sebetralstat and KVD824, targeting hereditary angioedema and diabetic macular edema. A live webcast will be available on the company’s website, with an audio archive accessible for 30 days post-event.

KalVista Pharmaceuticals (NASDAQ: KALV) announces the immediate appointment of Patrick A. Treanor to its Board, as part of a planned transition, succeeding Dan Soland, who has resigned. Treanor, currently COO of Pathalys Pharma, brings extensive experience in sales and marketing within the biopharmaceutical sector. His expertise is seen as vital for KalVista's evolution towards a pre-commercial phase, focusing on FDA approval and commercialization of key therapies, including sebetralstat and KVD824.

KalVista Pharmaceuticals has received approval for its drug candidate, sebetralstat, from the WHO and USAN. This medication is currently undergoing evaluation in a Phase 3 study named KONFIDENT, targeting on-demand treatment for hereditary angioedema (HAE) attacks. CEO Andrew Crockett expressed enthusiasm for sebetralstat's potential to be a groundbreaking oral therapy for HAE. The company is actively preparing for future regulatory submission while progressing with its ongoing clinical trials for sebetralstat and another drug, KVD824.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) will present at the 21st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 3:00 p.m. ET. A live webcast will be available on their website, with an audio archive accessible for 30 days post-event. KalVista focuses on developing oral protease inhibitors for unmet medical needs, particularly targeting hereditary angioedema and diabetic macular edema. Their candidates include KVD900, KVD824, and KVD001, currently in various clinical trial phases.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced the granting of inducement options to a newly-hired employee, allowing the purchase of 7,000 shares of common stock at an exercise price of $15.00 per share. This price matches the company’s closing stock price on the grant date of April 1, 2022. The options will vest quarterly over four years, contingent on the employee’s continued service. This grant adheres to Nasdaq Listing Rule 5635(c)(4), reflecting KalVista's commitment to attracting talent.

KalVista Pharmaceuticals (NASDAQ: KALV) announced new data on KVD900, a potent oral inhibitor targeting plasma kallikrein, crucial for hereditary angioedema (HAE) treatment. Published in Clinical & Experimental Allergy, the data highlight rapid absorption and effective plasma kallikrein inhibition. This supports ongoing Phase 3 KONFIDENT trials for KVD900 as an on-demand therapy for HAE attacks, reinforcing its potential to block harmful bradykinin generation.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has provided an operational update and financial results for the third fiscal quarter ending January 31, 2022. The company initiated the Phase 3 KONFIDENT trial for KVD900, aimed at treating HAE attacks, with data expected in H2 2023. The Phase 2 KOMPLETE trial for KVD824 is on track, with anticipated data in mid-2023. Financially, KalVista reported a net loss of $22.5 million and no revenue for the quarter. Research and development expenses increased to $19.7 million, reflecting heightened clinical trial activities.

KalVista Pharmaceuticals (NASDAQ: KALV) has initiated the Phase 3 KONFIDENT clinical trial for KVD900, aimed at evaluating its efficacy and safety as the first oral on-demand therapy for hereditary angioedema (HAE) attacks. The trial will involve approximately 84 participants across 60 sites in 20 countries, comparing two doses of KVD900 against a placebo. Results from the KONFIDENT trial are expected in the second half of 2023, with KVD900 designed to enhance treatment convenience over existing injectable therapies.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced the grant of inducement options to purchase 5,000 shares to a newly-hired employee on March 1, 2022. The options have an exercise price of $15.94 per share, equal to the stock's closing price on the grant date. One-fourth of the options will vest on the one-year anniversary, with the remainder vesting in monthly installments over three years, contingent on continued employment. KalVista focuses on small molecule protease inhibitors for unmet medical needs, including therapies for hereditary angioedema and diabetic macular edema.